BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment

BeOne Medicines AG (NASDAQ:ONC) is among the 12 best stocks to buy and hold for the next 2 years.

On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenues of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, increases of 33% and 40% from the prior-quarter and prior-year periods, respectively. Brukinsa, the company’s lymphoma and leukemia treatment, had revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, respectively, up 38% and 49% from the prior periods.

After the earnings report, on February 27, Truist Securities raised its price target on BeOne Medicines AG (NASDAQ:ONC) to $412 from $400 while maintaining a Buy rating on the stock. Truist adjusted its price target after incorporating the quarterly results, fiscal 2026 guidance, and insights from post-earnings discussions with the company.

Truist Securities noted BeOne Medicines AG (NASDAQ:ONC)’s fiscal 2026 revenue guidance of $6.2 billion to $6.4 billion roughly brackets consensus estimates of $6.4 billion and has led to added pressure on the shares. The analyst said that its current outlook on BeOne Medicines AG (NASDAQ:ONC) suggests healthy growth for Brukinsa even without any major label expansion.

BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment

Grail Inc.’s Galleri cancer test screening kit. Photo from Grail website

BeOne Medicines AG (NASDAQ:ONC) is a global oncology company that discovers and develops innovative treatments that are more affordable and accessible to cancer patients worldwide.

READ NEXT: 13 Hot Stocks to Buy with the Highest Upside Potential and 10 Best High-Upside Materials Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.